COMMITED FOR THE FUTURE OF PATHOLOGY
Our missionOur mission is to empower pathologists with non-destructive 3D histopathology that delivers greater diagnostic confidence, faster insights, and better outcomes for patients.
Management
Dr. Fabian Mohr
Managing Director
Head of Business Development
CO-FOUNDER
Fabian has 12+ years professional experience in cancer research, software development, strategy consulting and venture capital. He was holding several board mandates of life science companies prior joining LIMAA. He is responsible for business development, licensing, general management and overall strategy in the company.
Camila Tomikawa, MD
Head of MA & SA
Head of Pathology
CO-FOUNDER
Camila is a pathologist with a medical informatician MSc and has been working with several digital pathology startups as a Medical Advisor to build scalable and efficient digital pathology workflows and clinical decision support systems. As an expert in the field she advises on LIMAAs strategies for clinical validation and integration of products.
Dr. Dr. René Hägerling
ppa.
Head of Research
CO-FOUNDER
René has more than a decade experience in developing and adapting technology for 3D histology. As a chemist and medical doctor, he is responsible for the development of scientific breakthrough technologies in the company. He further is a group leader at Charité University Hospital Berlin where he focusses on 3D spatial histology.
Vanessa Kuhl
Head of Development
Vanessa is a marketing professional with experience in marketing management, event coordination, and HR marketing. She has led projects across brand communication and campaign support, combining creativity with a structured, hands-on approach.
Dr. Jennifer Doedt
Head of RA & QA
Jennifer is Head of RA & QA, strengthening our team with her expertise in regulatory affairs, quality management, and compliance. With extensive experience in highly regulated environments, she supports the translation of innovation into reliable, scalable, and standards-driven solutions.
Nadine Hülsemann
Head of Production
Nadine is a biologist with expertise in in vitro diagnostic (IVD) production. As Head of Production at LIMAA Technologies, she drives manufacturing efficiency through process optimization and automation, ensuring the consistent delivery of high-quality IVD solutions.
Dr. Georg Kox
Head of Marketing & Sales
Georg Kox is a seasoned healthcare entrepreneur with a strong focus on marketing, sales, and venture building. He supports the development of medical businesses from early-stage strategy to growth and successful exit. He is currently active at LIMAA Technologies.
Mélanie Guenter
Managing Director
Head of Business Development
CO-FOUNDER
As Co-Founder and Head of Operations & IT, Mélanie brings over two decades of experience at the intersection of lab environments, regulatory & quality management, software development, and operations – uniquely positioned to turn complex, regulated innovation into scalable, high-impact solutions.
History of the Company
LIMAA Technologies (LIght-sheet Microscopy and Automated Analysis) is a spin-off from the working group of Dr. Dr. René Hägerling from Charité - University Hospital in Berlin.
René, with over a decade of experience in three-dimensional tissue analysis, initially focused on embryonic vascular development when faced with limitations in standard two-dimensional histology methods. He played a pivotal role in testing light-sheet microscopes from German startups and companies, pioneering spatial visualization of the vascular system.
During the 2014 Lindau Nobel Laureate Meeting, René met Dr. Fabian Mohr, who had transitioned from oncology research to strategy consulting and venture capital. Their collaboration began in 2017, aiming to apply light-sheet microscopy to clinical diagnostics. They garnered interest from private health insurers, particularly for diagnosing lymphedema and lipoedema, where clear tests were lacking.
After earning degrees in Chemistry, Medicine, and a PhD in Biology and Imaging, René left the Max Planck Institute for Molecular Biomedicine in Münster for a residency at the Charité - University Hospital in Berlin. There, he continued developing light-sheet imaging-based diagnostics and, in 2019, entered the Berlin Institute of Health Digital Health Accelerator with Fabian. They evolved their concept into an automated platform for histopathology on entire tissue biopsies, departing from glass slide-based analyses.
In 2020, René and Fabian collaborated with Prof. Bruno Märkl from the University Hospital in Augsburg for a clinical feasibility study, yielding promising pilot data. In 2021, they secured EXIST funding to transform their scientific and clinical findings into products, marking the beginning of LIMAA Technologies. Subsequent support came from Prof. David Horst at Charité's Institute of Pathology, a European Research Council grant, and the establishment of LIMAA Technologies GmbH in 2022.
Get in Touch for More Information
If you are interested in learning more about our team, our technology and our vision feel free to reach out to us.